Tracer library / [131I]I-GMIB-4AH29

[131I]I-GMIB-4AH29

Also written as [I-131]I-GMIB-4AH29

Radionuclide: I-131 t½ 11549 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: single-domain antibody (sdAb)
Target / mechanism: Fibroblast activation protein alpha (FAP) PMID 42364406
Clinical application: FAP-positive cancers (cancer-associated fibroblasts of epithelial-derived cancers, pan-tumor target) PMID 38040444
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	—	>99.7%	SGMTB-Boc2	41390415 2025 J Transl Med N-succinimidyl 4-(1,2-bis-tert-butoxycarbonyl)guanidinomethyl-3-(trimethylstannyl)benzoate precursor (SGMTB- Boc2; 50–500 µg) dissolved in anhydrous acetonitrile (0.2-1 mL) was incubated for 10 min at RT with Na[131I]I

Need this precursor?We can point you to suppliers for [131I]I-GMIB-4AH29, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 39 from PMID 38040444: 'Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α.'.